New VP For Lilly Oncology

(photo courtesy Dana-Farber Cancer Institute)

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Indianapolis-based Eli Lilly & Co. (NYSE: LLY) has named Levi Garraway senior vice president of global development and medical affairs for Lilly Oncology. Garraway will begin his new role January 1, following the retirement of Richard Gaynor.

Garraway currently serves as professor of medicine at Harvard Medical School in Massachusetts. He is also the director of the Joint Center for Cancer Precision Medicine, which spans the Harvard teaching hospitals.

"We are pleased and honored to have Dr. Garraway join us at Lilly," said Sue Mahony, president of Lilly Oncology. "He has made a tremendous impact in his career and is recognized around the world as a leader in oncology. We know he will provide keen insight and expertise—and will continue to advance Lilly’s work in developing innovative new medicines to truly make life better for people with cancer around the world."

Garraway is also the co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center.